It also re-examines some of the conventional wisdom that previously dominated clinical trial design and discusses development and internal validation of a predictive biomarker as a new paradigm for ...
In this special series, we aimed to include a wide perspective from regulators, bioethicists, statisticians, and clinician-scientists on the drug development continuum, focusing on challenges raised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results